Abstract
Although immunotherapy has recently revolutionized standard of care in different cancer types, prostate cancer has generally failed to show dramatic responses to immune checkpoint inhibitors. As in other tumors, the goal in prostate cancer is now to target treatments more precisely on patient’s individual characteristics through precision medicine. Defects in mismatch repair, mutations in the exonuclease domain of the DNA polymerase epsilon (POLE), high tumor mutational burden and the presence of biallelic loss of CDK12 among others, are predictive biomarkers of response to immunotherapy. In the present review, we summarize the evolving landscape of immunotherapy in prostate cancer, including precision approaches and strategies to define classes of responsive patients and scale up resistance to immune checkpoint inhibitors.
Papers of special note have been highlighted as: • of interest; •• of considerable interest
References
- 1. Global Cancer Statistics 2020: GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
- 2. . Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin. Adv. Hematol. Oncol. 11(1), 14–23 (2013).
- 3. . The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell. Mol. Immunol. 17(8), 807–821 (2020).
- 4. . Cancer immunotherapy using checkpoint blockade. Science 359(6382), 1350–1355 (2018).
- 5. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411–422 (2010).
- 6. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, Phase 3 trial. Lancet Oncol. 15(7), 700–712 (2014).
- 7. Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer. Oncotarget 7(33), 52810–52817 (2016).
- 8. . Immune checkpoint blockade for prostate cancer: niche role or next breakthrough? Am. Soc. Clin. Oncol. Educ. Book. 40, 1–18 (2020).
- 9. . Immunotherapy of prostate cancer: facts and hopes. Clin. Cancer Res. 23(22), 6764–6770 (2017).
- 10. Immune-checkpoint inhibitors and metastatic prostate cancer therapy: learning by making mistakes. Cancer Treat. Rev. 88, 102057 (2020).
- 11. . The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat. Rev. Cancer 19(3), 133–150 (2019).
- 12. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, openlabel phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395–405 (2020). • Antitumor activity of pembrolizumab in a subset of patients with RECIST-measurable and bone-predominant metastatic castration resistant prostate cancer previously treated with docetaxel and targeted endocrine therapy.
- 13. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell 38(4), 489–499.e3 (2020).
- 14. . Aggressive-variant microsatellite-stable POLE mutant prostate cancer with high mutation burden and durable response to immune checkpoint inhibitor therapy. JCO Precis. Oncol. 2, 1–8 (2018).
- 15. MSH2 loss in primary prostate cancer. Clin. Cancer Res. 23(22), 6863–6874 (2017).
- 16. . Cyclin-dependent kinase 12, immunity, and prostate Cancer. N. Engl. J. Med. 379(11), 1087–1089 (2018).
- 17. Clinical features and therapeutic outcomes in men with advanced prostate cancer and DNA mismatch repair gene mutations. Eur. Urol. 75(3), 378–382 (2018).
- 18. . Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011). •• Additional hallmarks involved in the pathogenesis of cancers and enabling characteristics that drive tumor progression.
- 19. Genomic and molecular landscape of DNA damage repair deficiency across the Cancer Genome Atlas. Cell Rep. 23(1), 239–254 (2018). • Pan-cancer analysis of DNA damage repair deficiency in cancer using integrative genomic and molecular analyses to demonstrate the prognostic utility of DNA damage repair deficiency scores.
- 20. . BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat. Rev. Cancer 12(1), 68–78 (2011).
- 21. The emerging role of PARP inhibitors in prostate cancer. Expert Rev. Anticancer Ther. 20(8), 715–726 (2020).
- 22. . The role of the core non-homologous end joining factors in carcinogenesis and cancer. Cancers (Basel) 9(7), 81 (2017).
- 23. . Mutations in DNA repair genes are associated with increased neo-antigen load and activated T cell infiltration in lung adenocarcinoma. Oncotarget 9(8), 7949–7960 (2017).
- 24. Cancer Genome Atlas Research Network. The molecular taxonomy of primary prostate cancer. Cell 163(4), 1011–1025 (2015).
- 25. . primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168(4), 707–723 (2017).
- 26. DNA-repair defects and olaparib in metastatic prostate cancer. N. Engl. J. Med. 373(18), 1697–1708 (2015).
- 27. . BRCA2 and other DDR genes in prostate cancer. Cancers (Basel) 11(3), 352 (2019).
- 28. Genetic aberrations in DNA repair pathways: a cornerstone of precision oncology in prostate cancer. Br. J. Cancer 124(3), 552–563 (2021).
- 29. Tumour lineage shapes BRCA-mediated phenotypes. Nature 571, 576–579 (2019).
- 30. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N. Engl. J. Med. 375(5), 443–453 (2016). •• Multicenter study assessing the incidence of germline mutations in genes mediating DNA-repair processes among men with metastatic prostate cancer.
- 31. Microsatellite instability in prostate cancer by PCR or next-generation sequencing. J. Immunother. Cancer 6(1), 29 (2018).
- 32. . Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease. J. Immunother. Cancer 6(1), 35 (2018).
- 33. . The role of neoantigens in response to immune checkpoint blockade. Int. Immunol. 28(8), 411–419 (2016).
- 34. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med. 371(23), 2189–2199 (2014).
- 35. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 348(6230), 124–128 (2015).
- 36. The landscape of immune cells infiltrating in prostate cancer. Front. Oncol. 10, 517637 (2020).
- 37. . Comprehensive analysis of tumour mutational burden and its clinical significance in prostate cancer. BMC Urol. 21(1), 29 (2021).
- 38. Neoantigen responses, immune correlates, and favorable outcomes after ipilimumab treatment of patients with prostate cancer. Sci. Transl. Med. 12(537), eaaz3577 (2020).
- 39. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32(5), 661–672 (2021).
- 40. Harmonization of tumor mutational burden quantification and association with response to immune checkpoint blockade in non-small-cell lung cancer. JCO Precis. Oncol. 3, PO.19.00171 (2019).
- 41. . Tumor mutational burden as a predictor of immunotherapy response: is more always better? Clin. Cancer Res. 27(5), 1236–1241 (2021).
- 42. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther. 16(11), 2598–2608 (2017).
- 43. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
- 44. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443–2454 (2012).
- 45. . PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev. Clin. Pharmacol. 11(5), 475–486 (2018).
- 46. Comprehensive evaluation of programmed death ligand 1 expression in primary and metastatic prostate cancer. Am. J. Pathol. 188, 1478–1485 (2018).
- 47. Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. Ann. Oncol. 29, 1807–1813 (2018). • Evidence of durable objective response to pembrolizumab in a subset of patients with heavily pretreated, advanced programmed death-ligand 1-positive prostate cancer.
- 48. Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy. J. Clin. Invest. 128, 5137–5149 (2018).
- 49. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat. Rev. Clin. Oncol. 15, 325–340 (2018).
- 50. . Inflammation and cancer: advances and new agents. Nat. Rev. Clin. Oncol. 12, 584–596 (2015).
- 51. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 105, 93–103 (2011).
- 52. The immune contexture in cancer prognosis and treatment. Nat. Rev. Clin. Oncol. 14, 717–734 (2017).
- 53. . Predictive biomarkers for checkpoint inhibitor-based immunotherapy. Lancet Oncol. 17, e542–e551 (2016). •• Exploring tumor-infiltrating lymphocytes, tumor mutation burden, immune gene signatures and multiplex immunohistochemistry to assess predictive biomarker for checkpoint inhibitor-based immunotherapy.
- 54. CD4+CD25high T cells are enriched in the tumor and peripheral blood of prostate cancer patients. J. Immunol. 177, 7398–7405 (2006).
- 55. CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin. Cancer Res. 13, 6947–6958 (2007).
- 56. The immune landscape of prostate cancer and nomination of PD-l2 as a potential therapeutic target. J. Natl Cancer Inst. 111, 301–310 (2019).
- 57. Secreted factors from colorectal and prostate cancer cells skew the immune response in opposite directions. Sci. Rep. 5, 15651 (2015).
- 58. Abstract 3961: increased CCR4-positive regulatory T cells in biopsy specimen of poor prognosis prostate cancer. Cancer Res. 77, 3961 (2017).
- 59. A panoply of errors: polymerase proofreading domain mutations in cancer. Nat. Rev. Cancer 16(2), 71–81 (2016).
- 60. A recurrent cancer-associated substitution in DNA polymerase ε produces a hyperactive enzyme. Nat. Commun. 10(1), 374 (2019).
- 61. . POLE proofreading defects: contributions to mutagenesis and cancer. DNA Repair (Amst.) 76, 50–59 (2019).
- 62. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 5(10), 1504–1506 (2019).
- 63. 526O – high activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours. Ann. Oncol. 31(Suppl. 4), S462–S504 (2020).
- 64. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes. Genes Dev. 25(20), 2158–2172 (2011).
- 65. Tumor-infiltrating lymphocytes in biallelic-CDK12 mutated prostate cancer. J. Clin. Oncol. 36(Suppl. 15), 5070 (2018).
- 66. Inactivation of CDK12 delineates a distinct immunogenic class of advanced prostate cancer. Cell 173(7), 1770–1782.e14 (2018).
- 67. CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-ribose) polymerase inhibitors, and PD-1 inhibitors. JCO Precis. Oncol. (4), 370–381 (2020).
- 68. . Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 17(9), 559–572 (2017).
- 69. Clinical outcomes in cyclin-dependent kinase 12 mutant advanced prostate cancer. Eur. Urol. 77(3), 333–341 (2020).
- 70. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. Cancer Res. 60(9), 2444–2448 (2000).
- 71. Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter Phase I/II study. Ann. Oncol. 24(7), 1813–1821 (2013).
- 72. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35(1), 40–47 (2017).
- 73. Safety and clinical activity of atezolizumab in patients with metastatic castration-resistant prostate cancer: a Phase I study. Clin. Cancer Res. 27(12), 3360–3369 (2021).
- 74. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a Phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 18(5), 587–598 (2017).
- 75. A Phase 2 study of olaparib and durvalumab in metastatic castrate-resistant prostate cancer (mCRPC) in an unselected population. J. Clin. Oncol. 36(6), 163 (2018).
- 76. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J. Immunother. Cancer 6(1), 141 (2018).
- 77. KEYNOTE-365 cohort B: pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)–pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)—new data after an additional 1 year of follow-up. J. Clin. Oncol. 39(Suppl. 6), 10 (2021).
- 78. CheckMate 9KD arm B final analysis: efficacy and safety of nivolumab plus docetaxel for chemotherapy-naïve metastatic castration-resistant prostate cancer. J. Clin. Oncol. 39(Suppl. 6), 12 (2021).
- 79. Hostile, hypoxia-A2-adenosinergic tumor biology as the next barrier to overcome for tumor immunologists. Cancer Immunol. Res. 2, 598–605 (2014).
- 80. CD39/CD73 upregulation on myeloid-derived suppressor cells via TGF-β-mTOR-HIF-1 signaling in patients with non–small cell lung cancer. Oncoimmunology 6, e1320011 (2017).
- 81. . Targeting adenosine for cancer immunotherapy. J. Immunother. Cancer 6, 57 (2018).
- 82. Evidence of immune activation in the first-in-human Phase Ia dose escalation study of the adenosine 2a receptor antagonist, AZD4635, in patients with advanced solid tumors. Presented at: AACR Annual Meeting 2019. GA, USA (29 March-3 April 2019).
- 83. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).
- 84. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci. Transl. Med. 7, 303ra139 (2015).
- 85. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).
- 86. . Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5(9), 915–919 (2015).
- 87. . Acquired resistance to immunotherapy and future challenges. Nat. Rev. Cancer 16(2), 121–126 (2016).
- 88. . Adaptive resistance to cancer immunotherapy. Adv. Exp. Med. Biol. 1036, 213–227 (2017).
- 89. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 515(7528), 577–581 (2014).
- 90. . Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. J. Intern. Med. 283(2), 110–120 (2018).
- 91. Olaparib for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 382(22), 2091–2102 (2020). •• Results from PROfound trial. Olaparib was associated with longer progression-free survival and better measures of response and patient-reported endpoints than either enzalutamide or abiraterone.
- 92. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372(26), 2509–2520 (2015).
- 93. NCCN Guidlines for Prostate Cancer Version 2.2021. http://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459
- 94. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 31(9), 1119–1134 (2020).